CDA | Evidence Driven
CDA | Evidence Driven

Mekinist for Metastatic Melanoma - Details

Détails

Fichiers
Generic Name:
Trametinib
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Melanoma
Fabricant:
GlaxoSmithKline
Brand Name:
Mekinist
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0030-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
0.5 mg, 1.0 mg and 2.0 mg tablet
Tumour Type:
Peau et mélanome
Indications:
Metastatic Melanoma
Funding Request:
For use as a monotherapy for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
GlaxoSmithKline
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:

Fichiers

Provincial Funding Summary Résumé, financement provincial Afficher le PDF
Trametinib (Mekinist) for Metastatic Melanoma - pERC Final Recommendation Recommandation finale 22 octobre 2013 Afficher le PDF
Trametinib (Mekinist) for Metastatic Melanoma - Final Clinical Guidance Report Rapports d'orientation 22 octobre 2013 Afficher le PDF
Trametinib (Mekinist) for Metastatic Melanoma - Final Economic Guidance Report Rapports d'orientation 22 octobre 2013 Afficher le PDF
Trametinib (Mekinist) for Metastatic Melanoma - pERC Initial Recommendation Recommandation initiale 03 octobre 2013 Afficher le PDF
Trametinib (Mekinist) for Metastatic Melanoma - PAG Feedback on Initial Recommendation Rétroaction 22 octobre 2013 Afficher le PDF
Trametinib (Mekinist) for Metastatic Melanoma - Manufacturer (GlaxoSmithKline) Feedback on Initial Recommendation Rétroaction 22 octobre 2013 Afficher le PDF
Trametinib (Mekinist) for Metastatic Melanoma - Patient Advocacy Group (Melanoma Network of Canada) Feedback on Initial Recommendation Rétroaction 22 octobre 2013 Afficher le PDF
Trametinib (Mekinist) for Metastatic Melanoma - Patient Advocacy Group (MNC) COI Declarations Rétroaction 22 octobre 2013 Afficher le PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Dernière mise à jour : 02 septembre 2016